Literature DB >> 7678665

Differential role of brain ascending noradrenergic bundles in the circulatory effects of alpha-methyldopa and clonidine.

M Van den Buuse1, G A Head, P I Korner.   

Abstract

We examined the contribution of the ascending noradrenergic (NA) projections to the circulatory effects of intracisternal (i.c.) administration of clonidine and alpha-methyldopa (alpha-MD) in conscious rabbits. We compared the effects of combined dorsal and ventral NA fibre bundle lesions with those of individual bundle lesions. Local microinjection of 6-hydroxydopamine (6-OHDA) bilaterally into both NA fibre bundles in the midbrain produced marked reduction in norepinephrine (NE) after 4 weeks in all forebrain regions examined, but dopamine concentrations generally were not affected. The decreases in mean arterial pressure (MAP) and heart rate (HR) to i.c. injections of clonidine in animals with forebrain NE depletion were similar to those observed in vehicle-injected animals. In contrast, the normal decrease in HR produced by alpha-MD was abolished in rabbits with lesions of both the dorsal and ventral NA bundle (8% of control) and markedly reduced in rabbits with lesions of only the ventral bundle (33% of control). Lesions of the dorsal bundle alone produced a modest attenuation of bradycardia (62% of control). The effects of the lesions were not observed in sinoaortically denervated (SAD) rabbits, suggesting that the main component of the bradycardia affected was baroreflex vagal facilitation. The effects on the hypotension produced by alpha-MD were only slight.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678665     DOI: 10.1097/00005344-199301000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  1 in total

1.  Mediation of the hypotensive action of systemic clonidine in the rat by alpha 2-adrenoceptors.

Authors:  J P Hieble; D C Kolpak
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.